摘要
背景:即使在今天,阿尔茨海默病(AD)前驱阶段的可靠诊断依然是一个巨大的挑战。我们的研究主要集中在轻度认知功能障碍(MCI)认知功能下降的最早检测指标。由于即使在AD的轻度阶段也有语言障碍的报道,因此本研究的目的是开发一种灵敏的神经心理学筛选方法,该方法基于在执行记忆任务期间自发言语产生的分析。未来,这可以形成基于互联网的互动筛选软件的基础,以识别MCI。 方法:参与者为38名健康对照和48名临床诊断的MCI患者。引发自发言论,要求病人回忆两张黑白短片(一个是直接的,一个是延迟的),并回答一个问题。从记录的语音信号中首先手动(使用Praat软件)提取声学参数(犹豫比率,语速,长度和无声和充满暂停的数量,发声长度),然后自动地用自动语音识别(ASR )的工具。首先对提取的参数进行统计分析。然后,我们应用机器学习算法,根据声学特征来自动判别MCI和对照组。 结果:统计分析显示,大部分声学参数(发音速度,发音速率,无声暂停,犹豫比例,发音长度,每语停顿比率)存在显着差异。两组之间最显着的差异是在延迟回忆任务中的发言速度以及回答问题的停顿次数。分析过程的全自动化版本 - 即使用基于ASR的功能与机器学习相结合 - 能够以78.8%的F1分数分离两个类别。 结论:自发言语的时间分析可以用于实施一个新的,基于自动检测的工具,为社区筛选MCI。
关键词: 轻度认知障碍,自发言语,诊断,声学分析,时间特征,语音识别,机器学习。
Current Alzheimer Research
Title:A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech
Volume: 15 Issue: 2
关键词: 轻度认知障碍,自发言语,诊断,声学分析,时间特征,语音识别,机器学习。
摘要: Background: Even today the reliable diagnosis of the prodromal stages of Alzheimer's disease (AD) remains a great challenge. Our research focuses on the earliest detectable indicators of cognitive decline in mild cognitive impairment (MCI). Since the presence of language impairment has been reported even in the mild stage of AD, the aim of this study is to develop a sensitive neuropsychological screening method which is based on the analysis of spontaneous speech production during performing a memory task. In the future, this can form the basis of an Internet-based interactive screening software for the recognition of MCI.
Methods: Participants were 38 healthy controls and 48 clinically diagnosed MCI patients. The provoked spontaneous speech by asking the patients to recall the content of 2 short black and white films (one direct, one delayed), and by answering one question. Acoustic parameters (hesitation ratio, speech tempo, length and number of silent and filled pauses, length of utterance) were extracted from the recorded speech signals, first manually (using the Praat software), and then automatically, with an automatic speech recognition (ASR) based tool. First, the extracted parameters were statistically analyzed. Then we applied machine learning algorithms to see whether the MCI and the control group can be discriminated automatically based on the acoustic features.
Results: The statistical analysis showed significant differences for most of the acoustic parameters (speech tempo, articulation rate, silent pause, hesitation ratio, length of utterance, pause-per-utterance ratio). The most significant differences between the two groups were found in the speech tempo in the delayed recall task, and in the number of pauses for the question-answering task. The fully automated version of the analysis process – that is, using the ASR-based features in combination with machine learning - was able to separate the two classes with an F1-score of 78.8%.
Conclusion: The temporal analysis of spontaneous speech can be exploited in implementing a new, automatic detection-based tool for screening MCI for the community.
Export Options
About this article
Cite this article as:
A Speech Recognition-based Solution for the Automatic Detection of Mild Cognitive Impairment from Spontaneous Speech, Current Alzheimer Research 2018; 15 (2) . https://dx.doi.org/10.2174/1567205014666171121114930
DOI https://dx.doi.org/10.2174/1567205014666171121114930 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II B)
Current Medicinal Chemistry Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research Untangling Alzheimer’s Disease Clinicoanatomical Heterogeneity Through Selective Network Vulnerability – An Effort to Understand a Complex Disease
Current Alzheimer Research Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Intestinal Barrier Dysfunction Participates in the Pathophysiology of Ischemic Stroke
CNS & Neurological Disorders - Drug Targets An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus <i>Via</i> Activation of the VDAC1 Positive Feedback Loop
Current Alzheimer Research Niacin: From Mechanisms of Action to Therapeutic Uses
Mini-Reviews in Medicinal Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Models for Non-Alcoholic Fatty Liver Disease: A Link with Vascular Risk
Current Pharmaceutical Design